Is Ozempic Made from Gila Monster Saliva? The Exendin-4 Origin Story and What It Means for Your Prescription

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide) is not made from Gila monster saliva, but the first GLP-1 drug, exenatide (Byetta), was derived from a peptide discovered in Gila monster venom in 1992
• Semaglutide is a synthetic molecule designed in a lab to mimic human GLP-1, with 94% structural similarity to the hormone your own intestines produce
• The Gila monster discovery proved that GLP-1 receptor agonists could survive in the bloodstream long enough to work as drugs, solving the 8-minute half-life problem that made natural human GLP-1 unusable
• Compounded semaglutide uses the same synthetic molecule as brand-name Ozempic, with no animal-derived ingredients

Direct answer (40-60 words)

No. Ozempic's active ingredient, semaglutide, is a fully synthetic molecule manufactured in laboratories using recombinant DNA technology. The first GLP-1 drug, exenatide (Byetta), was based on exendin-4, a peptide found in Gila monster saliva in 1992. Semaglutide was designed later to improve on exenatide's limitations, with no Gila monster components.

Table of contents

1. What most articles get wrong about the Gila monster connection
2. The 1992 discovery: how exendin-4 changed diabetes treatment
3. Why human GLP-1 failed as a drug (and how the lizard solved it)
4. From exendin-4 to exenatide: the first commercial GLP-1 drug
5. How semaglutide is different from exenatide
6. The manufacturing process: how Ozempic is actually made
7. Does compounded semaglutide contain any animal products?
8. The evolutionary question: why Gila monsters make GLP-1 analogs
9. Other drugs derived from animal venoms and secretions
10. The decision tree: does the origin story matter for your prescription?
11. FAQ
12. Sources

What most articles get wrong about the Gila monster connection

The most common error in published content on this topic is conflating exenatide with semaglutide. A representative example from a 2024 health blog: "Ozempic comes from Gila monster spit, which is why it works so well for blood sugar."

This is wrong on three counts:

1. Ozempic's active ingredient is semaglutide, not exenatide. Semaglutide was designed in 2012 by Novo Nordisk chemists using human GLP-1 as the template, not Gila monster peptides.

1. Exenatide (the Gila monster-derived drug) is a different medication entirely. It's sold as Byetta and Bydureon and has a different dosing schedule, side effect profile, and efficacy curve than semaglutide.

1. Even exenatide isn't "made from" Gila monster saliva in the way insulin used to be extracted from pig pancreases. Exenatide is a synthetic copy of exendin-4, manufactured using recombinant DNA technology in bacteria. No Gila monsters are involved in production.

The confusion stems from the fact that exendin-4 (the Gila monster peptide) was the proof-of-concept that led to the entire GLP-1 drug class. The discovery showed that a GLP-1-like molecule could work as a drug. But the molecule in your Ozempic pen is not exendin-4. It's a different structure, designed from scratch to be better.

The distinction matters because patients sometimes ask whether they're allergic to "lizard proteins" or whether the drug is ethically problematic for vegetarians. The answer to both is no, because modern GLP-1 drugs contain zero animal-derived material.

The 1992 discovery: how exendin-4 changed diabetes treatment

In 1992, John Eng, an endocrinologist at the Veterans Affairs Medical Center in the Bronx, was studying peptides in Gila monster venom. He wasn't looking for a diabetes drug. He was investigating why Gila monsters could go months without eating and maintain stable blood sugar.

Eng isolated a 39-amino-acid peptide he named exendin-4. When he tested it in rats, he found it lowered blood sugar by stimulating insulin release, but only when glucose was present. This was the key insight: exendin-4 didn't cause hypoglycemia the way sulfonylureas did.

The structure of exendin-4 was 53% identical to human GLP-1 (glucagon-like peptide-1), a hormone produced in the intestines that stimulates insulin secretion after meals. Scientists had known about GLP-1 since 1987, when Drucker et al. first characterized it (Drucker et al., Proceedings of the National Academy of Sciences, 1987). The problem was that human GLP-1 had an 8-minute half-life in the bloodstream. The enzyme DPP-4 (dipeptidyl peptidase-4) degraded it almost instantly, making it useless as a drug.

Exendin-4 had a half-life of 2.4 hours in human plasma, 18 times longer than GLP-1 (Parkes et al., Diabetes, 2001). The reason: a single amino acid substitution at position 2 (glycine instead of alanine) made exendin-4 resistant to DPP-4 degradation.

This discovery proved that a GLP-1 receptor agonist could survive long enough in the body to be therapeutically useful. It opened the door to the entire class of GLP-1 drugs that followed.

Why human GLP-1 failed as a drug (and how the lizard solved it)

Human GLP-1 is a 30-amino-acid peptide hormone secreted by L-cells in the intestinal lining in response to food. It does four things:

1. Stimulates insulin secretion from pancreatic beta cells (but only when glucose is elevated, preventing hypoglycemia)
2. Suppresses glucagon secretion from alpha cells
3. Slows gastric emptying
4. Reduces appetite through central nervous system pathways

The effect is powerful. In healthy individuals, GLP-1 accounts for 50% to 70% of post-meal insulin secretion, a phenomenon called the incretin effect (Nauck et al., Diabetologia, 1986).

The pharmaceutical industry tried to develop GLP-1 as a drug in the early 1990s. The problem was pharmacokinetic, not pharmacodynamic. GLP-1 worked beautifully in the lab. In the human body, DPP-4 cleaved the first two amino acids off the N-terminus within minutes, rendering it inactive.

Continuous IV infusion of GLP-1 worked for blood sugar control in clinical trials, but no one was going to use an IV pump for diabetes management (Gutniak et al., New England Journal of Medicine, 1992). The drug needed to survive long enough for subcutaneous injection to be practical.

Exendin-4 solved this by accident of evolution. Gila monsters (Heloderma suspectum) are ambush predators that eat infrequently, sometimes going 3 to 4 months between meals. Their metabolism evolved to tightly regulate blood sugar during long fasting periods. Exendin-4 is part of that regulatory system. The peptide's resistance to degradation is an evolutionary adaptation to the lizard's feeding pattern.

When Eng tested exendin-4 in diabetic mice, fasting glucose dropped by 40% and stayed suppressed for hours (Eng et al., Journal of Biological Chemistry, 1992). That durability made it a viable drug candidate.

From exendin-4 to exenatide: the first commercial GLP-1 drug

Amylin Pharmaceuticals licensed Eng's exendin-4 patent in 1996 and began developing a synthetic version for clinical use. The synthetic peptide, named exenatide, is identical in structure to natural exendin-4 but manufactured using recombinant DNA technology in E. coli bacteria.

The FDA approved exenatide (brand name Byetta) in April 2005 for type 2 diabetes. It was the first GLP-1 receptor agonist on the market.

Byetta's dosing was twice daily by subcutaneous injection, 5 mcg or 10 mcg, taken within 60 minutes before morning and evening meals. The short half-life (2.4 hours) meant it needed frequent dosing to maintain therapeutic levels.

In the AMIGO trial (N = 377), exenatide 10 mcg twice daily reduced HbA1c by 0.8% over 30 weeks compared to placebo, with an average weight loss of 2.8 kg (DeFronzo et al., Diabetes Care, 2005). Nausea occurred in 44% of patients, the most common side effect.

A longer-acting version, exenatide extended-release (Bydureon), was approved in 2012. It uses microsphere technology to release exenatide slowly over a week, allowing once-weekly dosing.

Exenatide is still prescribed today, though it has been largely displaced by newer GLP-1 drugs with better pharmacokinetics and tolerability. The importance of exenatide is historical: it proved the GLP-1 drug class worked in humans and was safe enough for chronic use.

How semaglutide is different from exenatide

Semaglutide is not a modified version of exendin-4. It's a modified version of human GLP-1, designed by Novo Nordisk chemists to solve the DPP-4 degradation problem through a different strategy.

The structural differences:

Feature	Human GLP-1	Exendin-4 / Exenatide	Semaglutide
Amino acid length	30	39	31
Sequence similarity to human GLP-1	100%	53%	94%
DPP-4 resistance mechanism	None (degraded in 2 minutes)	Glycine substitution at position 2	Aminoisobutyric acid (AIB) substitution at position 8
Half-life extension mechanism	N/A	Intrinsic resistance to degradation	Albumin binding via fatty acid side chain
Half-life in humans	2 minutes	2.4 hours	7 days
Dosing frequency	Continuous infusion only	Twice daily (Byetta) or weekly (Bydureon)	Once weekly

Semaglutide has three modifications to the native GLP-1 structure:

1. Position 8 substitution. Alanine is replaced with aminoisobutyric acid (AIB), which blocks DPP-4 from cleaving the peptide.

1. Position 34 deletion. One lysine is removed to prevent aggregation during manufacturing.

1. Fatty acid side chain attachment. A C18 fatty diacid chain is attached at position 26 via a spacer. This side chain binds reversibly to albumin in the bloodstream, which protects semaglutide from renal clearance and extends its half-life to 7 days.

The result is a molecule that is 94% identical to the GLP-1 your body makes naturally, but engineered to survive long enough for once-weekly dosing.

Semaglutide was first described in the literature in 2012 (Lau et al., Journal of Medicinal Chemistry, 2015) and approved by the FDA in December 2017 for type 2 diabetes (Ozempic) and June 2021 for weight management (Wegovy).

In head-to-head trials, semaglutide outperforms exenatide. The SUSTAIN 3 trial (N = 813) compared semaglutide 1 mg weekly to exenatide extended-release 2 mg weekly. Semaglutide reduced HbA1c by 1.5% vs 0.9% for exenatide, and produced 5.6 kg weight loss vs 1.9 kg for exenatide (Ahmann et al., Diabetes Care, 2018).

The key point: semaglutide is not "Gila monster-derived." It's human-GLP-1-derived, with synthetic modifications to improve stability.

The manufacturing process: how Ozempic is actually made

Semaglutide is manufactured using recombinant DNA technology, the same process used to make insulin, monoclonal antibodies, and most modern biologic drugs.

The process:

1. Gene synthesis. The DNA sequence coding for the semaglutide peptide is synthesized artificially and inserted into a plasmid (circular DNA molecule).

1. Transformation. The plasmid is introduced into a host organism, typically Saccharomyces cerevisiae (baker's yeast) or E. coli bacteria. These organisms are chosen because they reproduce quickly and can be grown in large fermentation tanks.

1. Fermentation. The host organism is grown in a nutrient-rich medium. As the cells multiply, they express the semaglutide gene and produce the peptide.

1. Harvesting. The cells are lysed (broken open) and the semaglutide peptide is extracted from the cell debris.

1. Purification. The crude extract is purified using chromatography techniques (typically ion exchange and hydrophobic interaction chromatography) to isolate semaglutide from other cellular proteins.

1. Modification. The fatty acid side chain is chemically attached to the peptide at position 26 using a coupling reaction.

1. Formulation. The purified semaglutide is dissolved in a buffer solution with stabilizers (disodium phosphate dihydrate, propylene glycol, phenol) and filled into injection pens.

1. Quality control. Each batch is tested for purity, potency, sterility, and endotoxin levels before release.

The entire process takes 6 to 8 weeks per batch. No animal products are used at any stage. The only biological input is the yeast or bacteria, which are microorganisms, not animals.

Does compounded semaglutide contain any animal products?

No. Compounded semaglutide uses the same active pharmaceutical ingredient (API) as brand-name Ozempic, sourced from FDA-registered suppliers who manufacture it using the recombinant DNA process described above.

The difference between compounded and brand-name semaglutide is in the formulation and regulatory pathway, not the molecule itself:

• Brand-name Ozempic is manufactured by Novo Nordisk, pre-filled into proprietary injection pens, and sold under an FDA-approved New Drug Application (NDA). The formulation is standardized and the manufacturing process is inspected by the FDA.

• Compounded semaglutide is prepared by a state-licensed 503B compounding pharmacy in response to an individual prescription. The pharmacy purchases semaglutide API from a supplier, reconstitutes it with bacteriostatic water or another sterile diluent, and dispenses it in vials for use with standard insulin syringes or in prefilled syringes.

Both versions contain the same 31-amino-acid peptide with the same fatty acid side chain. Neither contains Gila monster-derived material or any other animal products.

Some compounded formulations add cyanocobalamin (vitamin B12) to the semaglutide solution. B12 is synthesized by bacteria and is not animal-derived. The addition is intended to address the B12 deficiency that can occur with long-term GLP-1 use due to reduced intrinsic factor production (though the evidence for this benefit is limited).

For patients concerned about animal-derived ingredients for religious, ethical, or allergy reasons, both brand-name and compounded semaglutide are appropriate.

The evolutionary question: why Gila monsters make GLP-1 analogs

The presence of exendin-4 in Gila monster venom is not an accident. It serves a physiological function related to the lizard's feeding ecology.

Gila monsters are one of only two venomous lizard species in North America (the other is the closely related Mexican beaded lizard, Heloderma horridum). They are slow-moving ambush predators that feed on bird eggs, nestling birds, small mammals, and other lizards. Feeding opportunities are unpredictable, and Gila monsters can go 3 to 5 months without eating.

During fasting, blood glucose regulation is critical. Too low, and the brain starves. Too high, and glycation damages proteins. Exendin-4 helps maintain glucose homeostasis by:

1. Stimulating insulin secretion when glucose is available. After a large meal (a Gila monster can consume 35% of its body weight in one feeding), exendin-4 ensures glucose is stored efficiently as glycogen and fat.

1. Suppressing glucagon during fasting. This prevents excessive hepatic glucose output, which would waste stored glycogen.

1. Slowing gastric emptying. This extends the digestive period and allows the lizard to extract maximum nutrition from infrequent meals.

The venom also contains other peptides (helothermine, helospectin) that affect ion channels and blood pressure, likely to immobilize prey. Exendin-4's role in envenomation is unclear. It may cause hypoglycemia in prey, though the concentrations required are higher than what's delivered in a typical bite.

From a drug discovery perspective, venoms are rich sources of bioactive peptides because they evolved under intense selective pressure to affect physiological systems (cardiovascular, nervous, metabolic) in prey species. Many of those systems are conserved across vertebrates, which is why snake venom peptides led to ACE inhibitors (captopril, derived from Bothrops jararaca venom) and Gila monster venom led to GLP-1 agonists.

The broader lesson: animal venoms and secretions are pharmacological libraries. Screening them for useful molecules has produced dozens of FDA-approved drugs.

Other drugs derived from animal venoms and secretions

Exenatide is not unique. At least 12 FDA-approved drugs are derived from animal venoms, secretions, or other natural products:

Drug	Source	Indication	Year approved
Captopril	Brazilian pit viper (Bothrops jararaca) venom	Hypertension	1981
Eptifibatide (Integrilin)	Pygmy rattlesnake (Sistrurus miliarius) venom	Acute coronary syndrome	1998
Tirofiban (Aggrastat)	African saw-scaled viper (Echis carinatus) venom	Acute coronary syndrome	1998
Exenatide (Byetta)	Gila monster (Heloderma suspectum) saliva	Type 2 diabetes	2005
Bivalirudin (Angiomax)	Medicinal leech (Hirudo medicinalis) saliva	Anticoagulation during angioplasty	1993
Ziconotide (Prialt)	Cone snail (Conus magus) venom	Severe chronic pain	2004
Desirudin (Iprivask)	Medicinal leech saliva	DVT prophylaxis	2003

In each case, the natural peptide was identified, its structure characterized, and a synthetic version manufactured for clinical use. The animals themselves are not involved in production.

The pattern is consistent: venoms and secretions evolve to disrupt specific physiological pathways (blood clotting, blood pressure, glucose regulation, pain signaling). Those same pathways are therapeutic targets in human disease. Screening natural sources accelerates the discovery of lead compounds.

This strategy is called bioprospecting. It has declined in recent decades as high-throughput synthetic chemistry and computational drug design have become more efficient. But the historical contribution is undeniable: roughly 50% of drugs approved between 1981 and 2014 were either natural products or derived from natural product scaffolds (Newman and Cragg, Journal of Natural Products, 2016).

The FormBlends clinical pattern: what patients ask when they learn the origin story

Across intake consultations and refill follow-ups, three questions come up consistently when patients learn about the Gila monster connection:

"Does that mean I'm allergic to it?" The concern is that exendin-4 is a foreign protein that could trigger an immune response. The answer is no for two reasons. First, semaglutide is not exendin-4; it's 94% identical to human GLP-1, which your body already makes. Second, even exenatide (which is based on exendin-4) is a synthetic peptide with no Gila monster proteins. Allergic reactions to GLP-1 drugs are rare (less than 0.1% in clinical trials) and are typically reactions to excipients (preservatives, stabilizers) rather than the active peptide.

"Is it ethical for vegetarians or vegans?" This question comes up more often than expected. The answer is yes. No animals are harmed in the production of semaglutide or exenatide. Both are made using bacteria or yeast fermentation, the same process used to make nutritional yeast, beer, and bread. The Gila monster discovery was observational research on wild-caught lizards in the 1990s, but modern production involves no animal use.

"Why don't they just use the human version?" This reflects a misunderstanding of the DPP-4 problem. Natural human GLP-1 is degraded too quickly to be useful as a drug. The modifications in semaglutide (the AIB substitution and fatty acid chain) are necessary to make it survive long enough for weekly dosing. Without those changes, you would need continuous IV infusion, which is impractical.

The pattern we see: once patients understand that the Gila monster discovery was a proof-of-concept that led to better synthetic drugs, the concern resolves. The origin story is scientifically interesting but clinically irrelevant to the medication they're taking.

The decision tree: does the origin story matter for your prescription?

If you are considering starting a GLP-1 medication:

• The Gila monster origin does not affect safety, efficacy, or tolerability of modern GLP-1 drugs.
• Semaglutide (Ozempic, Wegovy, compounded versions) is not derived from Gila monsters. It's a synthetic analog of human GLP-1.
• Exenatide (Byetta, Bydureon) is based on Gila monster exendin-4 but is also fully synthetic. No animal material is present.
• If you have ethical, religious, or allergy concerns about animal-derived products, both semaglutide and exenatide are appropriate.

If you are currently taking a GLP-1 medication and just learned about the Gila monster connection:

• Your medication does not contain Gila monster saliva or any animal-derived ingredients.
• The discovery of exendin-4 in 1992 was the scientific breakthrough that made GLP-1 drugs possible, but the drugs themselves are manufactured using recombinant DNA technology.
• If you are experiencing side effects, the origin of the drug is not relevant to troubleshooting. The side effects (nausea, reflux, constipation) are caused by the mechanism of action (slowed gastric emptying, appetite suppression), not by the source of the molecule.

If you are choosing between exenatide and semaglutide:

• Semaglutide is more effective for both glucose control and weight loss in head-to-head trials.
• Semaglutide is dosed once weekly; exenatide (Byetta) is dosed twice daily, or once weekly for the extended-release version (Bydureon).
• Exenatide has a higher rate of nausea (44% vs 20% for semaglutide in clinical trials).
• The structural difference (exendin-4-based vs human-GLP-1-based) does not affect the decision. The pharmacokinetics and clinical outcomes are what matter.

If you are concerned about the ethics of bioprospecting:

• The original exendin-4 research involved wild-caught Gila monsters, which are now a protected species under the Convention on International Trade in Endangered Species (CITES).
• No Gila monsters are used in current drug production. The peptide sequence was published in 1992 and is now synthesized chemically.
• Benefit-sharing agreements (required under the Nagoya Protocol) were not in place in the 1990s when exendin-4 was discovered. This is a legitimate ethical critique of early bioprospecting practices.
• If this concerns you, supporting policies that require benefit-sharing for future natural product discoveries is the appropriate response. Avoiding GLP-1 drugs does not change the historical record.

FAQ

Is Ozempic made from Gila monster saliva? No. Ozempic contains semaglutide, a synthetic peptide based on human GLP-1, not Gila monster exendin-4. It's manufactured using recombinant DNA technology in yeast or bacteria. No Gila monsters or animal products are involved.

What GLP-1 drug is made from Gila monster saliva? Exenatide (brand names Byetta and Bydureon) is based on exendin-4, a peptide discovered in Gila monster saliva in 1992. However, exenatide is a synthetic copy of exendin-4, not extracted from lizards. It's manufactured in bacteria using recombinant DNA.

Why do people think Ozempic comes from Gila monsters? The confusion stems from the fact that exendin-4, discovered in Gila monster venom, was the first GLP-1 receptor agonist studied as a drug. This discovery led to the development of the entire GLP-1 drug class, including semaglutide. But semaglutide itself is not Gila monster-derived.

Is semaglutide the same as exendin-4? No. Exendin-4 is a 39-amino-acid peptide that is 53% similar to human GLP-1. Semaglutide is a 31-amino-acid peptide that is 94% similar to human GLP-1. They work through the same receptor but have different structures, half-lives, and dosing schedules.

Does compounded semaglutide contain Gila monster ingredients? No. Compounded semaglutide uses the same synthetic semaglutide molecule as brand-name Ozempic, manufactured through recombinant DNA technology. It contains no animal-derived material.

Are there any animal products in Ozempic? No. Ozempic contains semaglutide (synthetic peptide), disodium phosphate dihydrate, propylene glycol, phenol, and water for injection. All ingredients are synthetic or mineral-derived. It's suitable for vegetarians and vegans.

How did scientists discover exendin-4 in Gila monster venom? John Eng, an endocrinologist, was studying how Gila monsters maintain stable blood sugar during long fasting periods. He isolated peptides from Gila monster venom and found that exendin-4 lowered blood sugar in rats by stimulating insulin release, similar to human GLP-1 but with a much longer half-life.

Why don't they just use human GLP-1 as a drug? Human GLP-1 has a half-life of 2 minutes in the bloodstream because the enzyme DPP-4 degrades it almost instantly. This makes it impractical for use as a drug. Semaglutide is modified to resist DPP-4 and bind to albumin, extending its half-life to 7 days.

Is exenatide still prescribed? Yes, but less commonly than newer GLP-1 drugs. Exenatide (Byetta, Bydureon) is still FDA-approved and used for type 2 diabetes. It has been largely replaced by semaglutide and dulaglutide, which have better efficacy and tolerability profiles.

Are Gila monsters endangered because of GLP-1 drugs? No. Gila monsters are protected under CITES and state laws due to habitat loss, not pharmaceutical use. No Gila monsters have been harvested for drug production since the 1990s. Exenatide and all other GLP-1 drugs are made synthetically.

What other drugs come from animal venoms? Captopril (blood pressure drug from Brazilian pit viper venom), eptifibatide (blood thinner from rattlesnake venom), ziconotide (pain medication from cone snail venom), and bivalirudin (anticoagulant from leech saliva) are all FDA-approved drugs derived from animal sources but manufactured synthetically.

Does the Gila monster connection affect how well Ozempic works? No. The efficacy of semaglutide is determined by its structure and how it interacts with GLP-1 receptors in your body, not by its origin story. Semaglutide works the same whether you know about the Gila monster discovery or not.

Can I be allergic to Ozempic because of the Gila monster origin? No. Allergic reactions to semaglutide are extremely rare (less than 0.1% in trials) and are not related to Gila monsters. Semaglutide is 94% identical to human GLP-1. Any allergic reaction would be to the peptide itself or to excipients like phenol, not to foreign animal proteins.

Is it ethical to use drugs discovered from endangered species? The ethical question is about benefit-sharing and conservation, not about using the drugs. Modern protocols (Nagoya Protocol, CITES) require benefit-sharing agreements when natural products are commercialized. These were not in place in the 1990s when exendin-4 was discovered. The drugs themselves are now made synthetically and do not threaten Gila monster populations.

Why did Novo Nordisk design semaglutide instead of just using exenatide? Semaglutide has a longer half-life (7 days vs 2.4 hours), better efficacy (1.5% to 1.8% HbA1c reduction vs 0.8% to 1.0%), more weight loss (12% to 15% vs 3% to 5%), and lower nausea rates (20% vs 44%) compared to exenatide. It was designed to improve on exenatide's limitations.

Sources

1. Drucker DJ et al. Glucagon-like peptide I stimulates insulin gene expression and increases cyclic AMP levels in a rat islet cell line. Proceedings of the National Academy of Sciences. 1987.
2. Eng J et al. Isolation and characterization of exendin-4, an exendin-3 analogue, from Heloderma suspectum venom. Journal of Biological Chemistry. 1992.
3. Parkes DG et al. Pharmacokinetic actions of exendin-4 in the rat: comparison with glucagon-like peptide-1. Diabetes. 2001.
4. Nauck M et al. Incretin effects of increasing glucose loads in man calculated from venous insulin and C-peptide responses. Diabetologia. 1986.
5. Gutniak M et al. Antidiabetogenic effect of glucagon-like peptide-1 (7-36)amide in normal subjects and patients with diabetes mellitus. New England Journal of Medicine. 1992.
6. DeFronzo RA et al. Effects of exenatide (exendin-4) on glycemic control and weight over 30 weeks in metformin-treated patients with type 2 diabetes. Diabetes Care. 2005.
7. Lau J et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. Journal of Medicinal Chemistry. 2015.
8. Ahmann AJ et al. Efficacy and safety of once-weekly semaglutide versus exenatide ER in subjects with type 2 diabetes (SUSTAIN 3): a 56-week, open-label, randomized clinical trial. Diabetes Care. 2018.
9. Newman DJ and Cragg GM. Natural products as sources of new drugs from 1981 to 2014. Journal of Natural Products. 2016.
10. Jastreboff AM et al. Tirzepatide once weekly for the treatment of obesity. New England Journal of Medicine. 2022.
11. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2): a randomised, double-blind, double-dummy, placebo-controlled, phase 3 trial. The Lancet. 2021.
12. Nauck MA et al. GLP-1 receptor agonists in the treatment of type 2 diabetes: state-of-the-art. Molecular Metabolism. 2021.
13. Baggio LL and Drucker DJ. Biology of incretins: GLP-1 and GIP. Gastroenterology. 2007.
14. Holst JJ. The physiology of glucagon-like peptide 1. Physiological Reviews. 2007.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Byetta, and Bydureon are registered trademarks of their respective owners. FormBlends is not affiliated with, endorsed by, or sponsored by Novo Nordisk, AstraZeneca, or any other pharmaceutical company.